Duration of humoral immunity and cross-neutralizing activity against the Alpha, Beta, and Delta variants after wild-type SARS-CoV-2 infection: A prospective cohort study

A prospective cohort study was conducted for adults diagnosed with COVID-19. Convalescent blood was obtained at 4, 6, and 11 months after SARS-CoV-2 infection. The seropositivity of anti-spike antibody was maintained in all patients (100%) until 11 months after COVID-19. Neutralizing antibody levels...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infectious diseases 2022-02
Main Authors: Noh, Ji Yun, Yang, Jeong-Sun, Hwang, Soon Young, Hyun, Hakjun, Seong, Hye, Yoon, Jin Gu, Yoon, Soo-Young, Cheong, Hee Jin, Kim, Woo Joo, Park, Woo-Jung, Kim, Jun-Won, Lee, Joo-Yeon, Song, Joon Young
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page
container_issue
container_start_page
container_title The Journal of infectious diseases
container_volume
creator Noh, Ji Yun
Yang, Jeong-Sun
Hwang, Soon Young
Hyun, Hakjun
Seong, Hye
Yoon, Jin Gu
Yoon, Soo-Young
Cheong, Hee Jin
Kim, Woo Joo
Park, Woo-Jung
Kim, Jun-Won
Lee, Joo-Yeon
Song, Joon Young
description A prospective cohort study was conducted for adults diagnosed with COVID-19. Convalescent blood was obtained at 4, 6, and 11 months after SARS-CoV-2 infection. The seropositivity of anti-spike antibody was maintained in all patients (100%) until 11 months after COVID-19. Neutralizing antibody levels against the wild-type SARS-CoV-2 gradually decreased but remained positive in more than 50% of patients 11 months after diagnosis: 98.5% (67/68) at 4 months, 86.8% (46/53) at 6 months, and 58.8% (40/68). However, cross-neutralizing activity against the Beta and Delta variants was attenuated 2.53-fold and 2.93-fold, respectively, compared to the wild-type strain.
format article
fullrecord <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_35172333</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>35172333</sourcerecordid><originalsourceid>FETCH-pubmed_primary_351723333</originalsourceid><addsrcrecordid>eNqFT11Lw0AQPASx1foXZH-AB0mvTcC32Co-W_G1rMmlWcl9cLcXif_If2ki-uzLDMPMsDtnYplvVSmLIlcLcRnje5ZlG1WUF2Khtnm5Vkotxdc-BWRyFlwLXTIuYA9kTLLEI6BtoA4uRml14smiT7InwJpp-PFPSDYycKeh6n2Ht3CvecK5uNc9IwwYCC1HwJZ1gA_qG8mj13Cong9y517lGsi2up6fuIMK_HTPz3LQULvOBYbIqRlX4rzFPurrX74SN48PL7sn6dOb0c3RBzIYxuPfNvVv4BuzQVyr</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Duration of humoral immunity and cross-neutralizing activity against the Alpha, Beta, and Delta variants after wild-type SARS-CoV-2 infection: A prospective cohort study</title><source>Oxford Journals Online</source><creator>Noh, Ji Yun ; Yang, Jeong-Sun ; Hwang, Soon Young ; Hyun, Hakjun ; Seong, Hye ; Yoon, Jin Gu ; Yoon, Soo-Young ; Cheong, Hee Jin ; Kim, Woo Joo ; Park, Woo-Jung ; Kim, Jun-Won ; Lee, Joo-Yeon ; Song, Joon Young</creator><creatorcontrib>Noh, Ji Yun ; Yang, Jeong-Sun ; Hwang, Soon Young ; Hyun, Hakjun ; Seong, Hye ; Yoon, Jin Gu ; Yoon, Soo-Young ; Cheong, Hee Jin ; Kim, Woo Joo ; Park, Woo-Jung ; Kim, Jun-Won ; Lee, Joo-Yeon ; Song, Joon Young</creatorcontrib><description>A prospective cohort study was conducted for adults diagnosed with COVID-19. Convalescent blood was obtained at 4, 6, and 11 months after SARS-CoV-2 infection. The seropositivity of anti-spike antibody was maintained in all patients (100%) until 11 months after COVID-19. Neutralizing antibody levels against the wild-type SARS-CoV-2 gradually decreased but remained positive in more than 50% of patients 11 months after diagnosis: 98.5% (67/68) at 4 months, 86.8% (46/53) at 6 months, and 58.8% (40/68). However, cross-neutralizing activity against the Beta and Delta variants was attenuated 2.53-fold and 2.93-fold, respectively, compared to the wild-type strain.</description><identifier>EISSN: 1537-6613</identifier><identifier>PMID: 35172333</identifier><language>eng</language><publisher>United States</publisher><ispartof>The Journal of infectious diseases, 2022-02</ispartof><rights>The Author(s) 2022. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35172333$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Noh, Ji Yun</creatorcontrib><creatorcontrib>Yang, Jeong-Sun</creatorcontrib><creatorcontrib>Hwang, Soon Young</creatorcontrib><creatorcontrib>Hyun, Hakjun</creatorcontrib><creatorcontrib>Seong, Hye</creatorcontrib><creatorcontrib>Yoon, Jin Gu</creatorcontrib><creatorcontrib>Yoon, Soo-Young</creatorcontrib><creatorcontrib>Cheong, Hee Jin</creatorcontrib><creatorcontrib>Kim, Woo Joo</creatorcontrib><creatorcontrib>Park, Woo-Jung</creatorcontrib><creatorcontrib>Kim, Jun-Won</creatorcontrib><creatorcontrib>Lee, Joo-Yeon</creatorcontrib><creatorcontrib>Song, Joon Young</creatorcontrib><title>Duration of humoral immunity and cross-neutralizing activity against the Alpha, Beta, and Delta variants after wild-type SARS-CoV-2 infection: A prospective cohort study</title><title>The Journal of infectious diseases</title><addtitle>J Infect Dis</addtitle><description>A prospective cohort study was conducted for adults diagnosed with COVID-19. Convalescent blood was obtained at 4, 6, and 11 months after SARS-CoV-2 infection. The seropositivity of anti-spike antibody was maintained in all patients (100%) until 11 months after COVID-19. Neutralizing antibody levels against the wild-type SARS-CoV-2 gradually decreased but remained positive in more than 50% of patients 11 months after diagnosis: 98.5% (67/68) at 4 months, 86.8% (46/53) at 6 months, and 58.8% (40/68). However, cross-neutralizing activity against the Beta and Delta variants was attenuated 2.53-fold and 2.93-fold, respectively, compared to the wild-type strain.</description><issn>1537-6613</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNqFT11Lw0AQPASx1foXZH-AB0mvTcC32Co-W_G1rMmlWcl9cLcXif_If2ki-uzLDMPMsDtnYplvVSmLIlcLcRnje5ZlG1WUF2Khtnm5Vkotxdc-BWRyFlwLXTIuYA9kTLLEI6BtoA4uRml14smiT7InwJpp-PFPSDYycKeh6n2Ht3CvecK5uNc9IwwYCC1HwJZ1gA_qG8mj13Cong9y517lGsi2up6fuIMK_HTPz3LQULvOBYbIqRlX4rzFPurrX74SN48PL7sn6dOb0c3RBzIYxuPfNvVv4BuzQVyr</recordid><startdate>20220216</startdate><enddate>20220216</enddate><creator>Noh, Ji Yun</creator><creator>Yang, Jeong-Sun</creator><creator>Hwang, Soon Young</creator><creator>Hyun, Hakjun</creator><creator>Seong, Hye</creator><creator>Yoon, Jin Gu</creator><creator>Yoon, Soo-Young</creator><creator>Cheong, Hee Jin</creator><creator>Kim, Woo Joo</creator><creator>Park, Woo-Jung</creator><creator>Kim, Jun-Won</creator><creator>Lee, Joo-Yeon</creator><creator>Song, Joon Young</creator><scope>NPM</scope></search><sort><creationdate>20220216</creationdate><title>Duration of humoral immunity and cross-neutralizing activity against the Alpha, Beta, and Delta variants after wild-type SARS-CoV-2 infection: A prospective cohort study</title><author>Noh, Ji Yun ; Yang, Jeong-Sun ; Hwang, Soon Young ; Hyun, Hakjun ; Seong, Hye ; Yoon, Jin Gu ; Yoon, Soo-Young ; Cheong, Hee Jin ; Kim, Woo Joo ; Park, Woo-Jung ; Kim, Jun-Won ; Lee, Joo-Yeon ; Song, Joon Young</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-pubmed_primary_351723333</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Noh, Ji Yun</creatorcontrib><creatorcontrib>Yang, Jeong-Sun</creatorcontrib><creatorcontrib>Hwang, Soon Young</creatorcontrib><creatorcontrib>Hyun, Hakjun</creatorcontrib><creatorcontrib>Seong, Hye</creatorcontrib><creatorcontrib>Yoon, Jin Gu</creatorcontrib><creatorcontrib>Yoon, Soo-Young</creatorcontrib><creatorcontrib>Cheong, Hee Jin</creatorcontrib><creatorcontrib>Kim, Woo Joo</creatorcontrib><creatorcontrib>Park, Woo-Jung</creatorcontrib><creatorcontrib>Kim, Jun-Won</creatorcontrib><creatorcontrib>Lee, Joo-Yeon</creatorcontrib><creatorcontrib>Song, Joon Young</creatorcontrib><collection>PubMed</collection><jtitle>The Journal of infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Noh, Ji Yun</au><au>Yang, Jeong-Sun</au><au>Hwang, Soon Young</au><au>Hyun, Hakjun</au><au>Seong, Hye</au><au>Yoon, Jin Gu</au><au>Yoon, Soo-Young</au><au>Cheong, Hee Jin</au><au>Kim, Woo Joo</au><au>Park, Woo-Jung</au><au>Kim, Jun-Won</au><au>Lee, Joo-Yeon</au><au>Song, Joon Young</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Duration of humoral immunity and cross-neutralizing activity against the Alpha, Beta, and Delta variants after wild-type SARS-CoV-2 infection: A prospective cohort study</atitle><jtitle>The Journal of infectious diseases</jtitle><addtitle>J Infect Dis</addtitle><date>2022-02-16</date><risdate>2022</risdate><eissn>1537-6613</eissn><abstract>A prospective cohort study was conducted for adults diagnosed with COVID-19. Convalescent blood was obtained at 4, 6, and 11 months after SARS-CoV-2 infection. The seropositivity of anti-spike antibody was maintained in all patients (100%) until 11 months after COVID-19. Neutralizing antibody levels against the wild-type SARS-CoV-2 gradually decreased but remained positive in more than 50% of patients 11 months after diagnosis: 98.5% (67/68) at 4 months, 86.8% (46/53) at 6 months, and 58.8% (40/68). However, cross-neutralizing activity against the Beta and Delta variants was attenuated 2.53-fold and 2.93-fold, respectively, compared to the wild-type strain.</abstract><cop>United States</cop><pmid>35172333</pmid></addata></record>
fulltext fulltext
identifier EISSN: 1537-6613
ispartof The Journal of infectious diseases, 2022-02
issn 1537-6613
language eng
recordid cdi_pubmed_primary_35172333
source Oxford Journals Online
title Duration of humoral immunity and cross-neutralizing activity against the Alpha, Beta, and Delta variants after wild-type SARS-CoV-2 infection: A prospective cohort study
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T22%3A55%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Duration%20of%20humoral%20immunity%20and%20cross-neutralizing%20activity%20against%20the%20Alpha,%20Beta,%20and%20Delta%20variants%20after%20wild-type%20SARS-CoV-2%20infection:%20A%20prospective%20cohort%20study&rft.jtitle=The%20Journal%20of%20infectious%20diseases&rft.au=Noh,%20Ji%20Yun&rft.date=2022-02-16&rft.eissn=1537-6613&rft_id=info:doi/&rft_dat=%3Cpubmed%3E35172333%3C/pubmed%3E%3Cgrp_id%3Ecdi_FETCH-pubmed_primary_351723333%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/35172333&rfr_iscdi=true